Introduction
C�������� b�l��g �� � ��m�ly �� �����m�mb�����u� �������� m�l��ul�� ���� ��� �m������� �� m���������g ��ll ��l����y ��� tissue integrity (1) . T��y ��� m������ ��l��um-��������� ��ll-��-��ll �������� by ����������g w��� ��� �y���l��m���� ��������, α, β, ��� γ (2, 3) . T�� �������� l��k ��������� �� ��� ����� �y���k�l����, bu� �l�� ��v� ��g��l��g �u������� �� ����� �w�. Ov�� ��� y����, >20 �y��� �� ��������� ��v� b��� identified and characterized, including the original E-, P-and N-cadherin (Type I), and cadherins 5 to 12 (Type II) (1) (2) (3) (4) . W��l� ��� �w� �ubg��u�� ����� ���u��u��l ��m�l�������, ���y ����b�� �u�������gly l���l� ��qu���� ��m�l�gy. C�������� ��� ��v�lv�� �� ���m�l m�mm��y gl��� ��v�l��m��� ��� function, and they appear to influence breast cancer and its clinical outcome (1, (3) (4) (5) (6) . Berx and van Roy (7) ��v��w�� ��� ��l� �� ��������� �� m�l�g���� �������, ��� �� ��� b��� ��m��-������� ���� l��� �� E-�������� ���������� w�� ���������� w��� ��������� ��v���v����� ��� ��������� ���������������. I���������gly, ��-���u����� �� E-�������� �� ��v���v� b����� ������ ��ll� ��� ��� ���ul� �� � l��� �gg�����v� b���v��� in vitro, �����by �ugg�����g ���� E-�������� �� ������ �� ��������� �� � more invasive phenotype than a causative factor (3, 5, 8) .
Cadherin-11, also known as OB-cadherin was first identified in mouse osteoblasts and is normally expressed in cells w��� � m������ym�l ������y��, ���lu���g ��� m������ym� �� the kidney and brain during development (8, 9) . C�������-11 �� �l�� ��������� �� �����l�g� �y��v���y��� ��� �� �� �m���-���� m������� �� ��� �y��v���y�� �������� ���� ����������z�� rheumatoid arthritis (10) . I� ��� ��ul�, ��������-11 �� �����gly ��������� �� b��� �� w�ll �� ������� ������� ���� m��������z� �� bone (11) . While the exact expression profile of cadherin-11 in ���l��y m�mm��y gl��� �� ��� k��w�, �� ��� b��� ���w� ���� it interacts with the fibroblast growth factor (FGF) signaling pathway (2, 8, 12) , ��� ��u� m��ul���� ��� �������� �� g��w�� �������. C�������-11 �� �y����lly ��������� �� m��y �y��� �� ���������g m������ym� ��� w��� ��������� �� ������l�um, EMT is thought to have occurred (12) (13) (14) (15) (16) (17) . I� m�y �l�� ���v��� ��� ��ll w��� �� �b�l��y �� ����bl��� ����l� ���� ��� b��� ��v����-ment (5, 11) . The majority of patients that succumb to breast (or ��������) ������ ��v� m��������� �� ��� �k�l����. I� �� �����bl� ���� ����� ��������-11-���������g �um�� ��ll� ����v��� ������ ������l���� �� �����bl����, ��������g �� ��� �y�� �� ������ metastasis, leading to bone remodeling (11) .
W��l� ��� ������� ��l� �� ��������� �� ������ ��m���� u��l���, ���y ��� �m������� �� ��� b���� �v���� ��� ��������� in breast cancer tumorigenesis (4, 12) . S�v���l �v���� �� �um���g������ ��� �����gly ��������� �� ����g�� �� �������� expression (14) (15) (16) (17) (18) . O�� ���m�l� �� �������� �w������g, w���� ��������� ����g� ���m ����� ��������� �� ������l��l cells to those predominant in mesenchymal cells (8) . T��� �v��� �� ���� �� � ������� ���� �� v���l �� m�l�g���� ����g�, the epithelial-mesenchymal transition (EMT). EMT is a key biologic process that was initially identified as a developmental ���g��m ���� ���bl�� ��l���z�� ������l��l ��ll� �� ��qu��� � motile mesenchymal phenotype (13) (14) (15) (16) (17) 19, 20) . T��� ���������� results in a more invasive and metastatic phenotype (15) (16) (17) 19) . R������� �ugg���� ���� �������� �w������g �� ��qu���� ��� ��������� m���l��y bu� ��� ��� ��� m�����l�g���l ����g�� ���� accompany EMT (13, 19) . T�� ��v���� ������� �� EMT, ��� mesenchymal-epithelial transition (MET) involves the conversion of mesenchymal cells to their epithelial derivatives (14) . I� �������m� ���g�������, ������v����� �� ��� EMT ���g��m ���m���� �um�� m��������� by ���v��g �um�� ��ll ��v����� and enhancing tumor cell survival (16, 17) . T���� ����g�� ��� ��g�ly �y��m�� ��� m��y �����m������ ������y��� �����. Dub���-M�����ll et al (16) ������b�� �w� �������� �����bl� m�������m� �� EMT ������g �� b����� ������, ��� �� w���� �� uncoupled from cadherin switching. Some difficulty lies in the ���� ���� �� �� ��� y�� �ully u��������� ��w ��������� ������-sion profiles change in EMT. This emanates from the fact ���� ����� ��� mul���l� w�y� �� ��gul��� �������� ����������, and many, but not all of these overlap (2) . R�����ly, ��������� w��� ��m��������� �� ��gul��� ���m ��ll m���������� ��� differentiation (20) . T�� u�� �� m������ym�l ���m ��ll� ��� ����u� ������ ��qu���� ��� m�g������ ��� ��m��g �� ��� ���� �� ��m�g�� ����u� ��� �� ��� b��� ���w� ���� b��� ��� m�g��-���y ��� ���l��������� ��������l �� ����� ��ll� ��� �������� by cadherin-2 and cadherin-11 (20) .
P���v���� et al (6) ��v� ��m��������� ���� ��������-11 mRNA ��� �������, �� w�ll �� � ��������-11 v������ mRNA ��� ��������� �� ��v���v� ��� ����ly �������������� b����� ������ ��ll l����. I� ����� ��ll�, ��������-11 �� l���l�z�� �� ��� ��ll m�mb���� �� � �����g���-��lubl� ��m�l��, w���� �� ���������� w��� α ��� β-�������, ��� m�y ����l����� �um�� ��ll ��v����� ��� m���������. A������� et al ��� D�k�����mu���y et al (21, 22) ��m��������� ���� ��������-11 �� ��������� �� ���ly ���g�� �� �um�� b����� ������ ��� �� ����� m�l�g�������. W��� ��m����� �� ���l��y b����� ����u�, ��������-11 w�� m��k��ly �l�v���� �� DCIS ��� �l�� �� ��� ����m� �� ��v���v� b����� ������� ��m����� �� ���m�l ����m�. While this seems counter-intuitive at first, it illustrates that the �u�������l ��v�����y �� ��������� �� ��y���l�g���l ��ll �� �l�� reflected in processes connected to malignant disease.
T���� �� ��u���y �� ��u���� �v�lu����g ��������-11 ������-���� �� �um�� ��v���v� b����� ������. T�� ��m �� ��� ������� ��u�y w�� �� ��v����g��� ��������-11 ���������� �� m�l�g���� b����� ����u� ��m�l�� ��� b���g� ���/�� ���l��y b����� ����u� ��m�l��. T�� ���������� w�� ���� �����l���� w��� ��v���l �l����������l�g���l ����m�����.
Materials and methods
Patient samples. Human breast tissue microarray (TMA) slides were obtained from US Biomax Inc. (Rockville, MD, USA). T���� TMA� �������� �� m�l�g���� ��� b���g� b����� �um���, ��� ���l��y b����� ����u� ��j����� �� � m�l�g���� �um�� �� ���m w�m�� u����g���g ���u����� m�mm��l���y. Cl�����-�����l�g���l �����m����� w�� �b������, ���lu���g �g�, �um�� g����, �um�� ��z� ��� �����l�gy. H��m��� �������� ����u�, �.g., �����g��, ���g�������� ��� HER2, �� w�ll �� ��������-11 expression were analyzed using immunohistochemistry (IHC).
Immunohistochemistry for cadherin-11. T���u� �������� �� paraffin-embedded formalin-fixed tissue blocks were deparaffinized with xylene for 5 min each, followed by two washes w��� 100% ������l ��� 10 m��. T�� �l���� w��� ���� ���ub���� in 95% ethanol for another 10 min and washed with dH 2 O �w��� for 5 min. Antigen retrieval was performed by placing slides in 10 mm�l/l citrate buffer (pH 6.0) and microwave treatment for 15 min. Tissue sections were cool down to room temperature (RT), washed in phosphate-buffered saline (PBS) and distilled w����. A����w����, �������� w��� bl��k�� w��� Ul��� V Bl��k (Lab Vision, Westinghouse Drive, Fremont, CA, USA) for 4 m��. A���� � ������u��v� PBS w���, �l���� w��� ���ub���� w��� ��� m����l���l M�u�� ���� ��������-11 IgG2B Cl��� # 283416 Catalog Number: MAB1790 (R&D Systems). Nega��v� ������l� w��� ������m�� �� �ll ����u� �������� by ���l����g ���m��y ����b����� w��� ��lu��� ����y�� �mmu��gl�bul�� (ImmunoCruz™ Staining system, Santa Cruz Biotechnology). T��� ��� �l���� w��� ���ub���� w��� g��� ����-��lyv�l��� ��� streptavidin-HRP (both Lab Vision) for 60 min, followed by an incubation with 3-amino-9-ethylcarbazole (AEC). Finally, �l���� w��� w����� �� PBS, ��u����������� w��� ��m����yl�� for 5 sec and cover-slipped.
Semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) for Cadherin-11.
A total of 0.5-1 µg of total RNA w�� ��������� ���m ���� �� ��� b����� ������ ��m�l��, subsequently subjected to DNase (RNase-Free DNase Set; Q��g��, H�l���, G��m��y) �����m��� ��� ���� ���ub���� w��� 0.5 µg/µl random hexamers (Promega Corp., M������, WI, USA). The final volume was adjusted to 5 µl with diethyl pyrocarbonate-treated double distilled water (DEPC-treated ��H 2 O), before being heat-denatured at 70˚C for 5 min and ���ll�� �� ���. T�� ��m�l�� w��� ���� ����� �� � �������� mix consisting of 4 µl of 5X RT-buffer (250 mM Tris-HCl, pH 8.3, 375 mM KCl, 15 mM MgCl 2 ), 2 µl dNTP mix stock solution (10 mM each Pharmacia Biotech, Uppsala, Sweden), 1 µl RNase inhibitor (Applied Biosystems, Vienna, Austria), 1 µl dithiothreitol (DTT), and 1 µl MMLV (Moloney murine leukemia virus)-RT (200 U/µl, Amersham Bioscience Ltd.). The reaction mix was vortexed and centrifuged briefly before being incubated at 37˚C for 1 h. The reaction was stopped by heating to 80˚C for 10 min. The tubes were chilled briefly on ice before they were centrifuged and stored at -20˚C.
PCR was performed by adding 20 µl reaction mix to 2.5 µl 10X PCR-buffer, 2 µl dNTP mix (10 mM each; New England Biolabs, Hertfordshire, UK), 0.25 µl primer (100 µM), 5 µl Taq polymerase (5 U/ml) to the cadherin-11 primers 
Evaluation of immunohistochemical staining and statistical analysis.
Immu��������� �l���� w��� ������ u���� � microscope (Olympus BX51; Olympus, Tokyo, Japan). The �������g ��������y �� ���m��� ��������� w�� ������ ��������g �� R�mm�l� et al (23) . T�� HER2 �������� ����u� ��� b��� evaluated according to standardized assessment (24) . O�ly �l���� w��� � IHC 3+ ����u� �� HER2 ��������� w��� categorized as positive. Chi-square and Student's t-test were u��� �� ��m���� ��������-11 ������� ���������� ��� �g�. A����������� b��w��� ��������-11 ��� �l�����l-�����l�g���l parameters were analyzed using Pearson's rho correlation test (2-sided). For all analyses, P<0.05 was considered to indicate � ����������lly ��g�������� ����������. D��� w��� ���lyz�� using SAS version 8.1 (SAS Institute Inc., Cary, NC, USA). 
Results
A ����l �� 82 m�l�g���� �um�� ��m�l�� ��� 70 ���l��y b����� ����u� ��� b���g� b����� l������ w��� ���lyz�� by IHC ��� ��m�-qu��������v� RT-PCR. T�� ������� �um�� ��������������� ��� ���w� �� T�bl� I. T�� m����� �g� �� ��� �������� w��� malignant tumors was 51 years, and median age of patients w��� b���g� �� ���l��y ����u� w�� 48 y����. T�� ���������� �� median age was not statistically significant. Of the malignant tumors, 75% (n=62) were infiltrating ductal carcinomas, and the remaining histological types included infiltrating lobular carcinomas (n=3) and otherwise specified (n=17). Regarding tumor size, 56% of malignant tumors were stage 2 (n=45), 24.4% were stage 1 (n=20), 19.5% were stage T3 (n=16), and 1% were stage 4 (n=1). The majority of tumors were grade 2 (53.7%, n=44), followed by grade 1 (18.3%, n=15) and Grade 3 (17%, n=14). In 9 cases (11%), the tumor grades were unknown. T�� �����g�� �������� ����u� w�� ������v� �� 71% �� ��� ��m�l�� (n=58), negative in 19.5% of cases (n=16), with 9.8% (n=8) u�k��w�. T�� ���g�������� �������� ����u� w�� ������v� �� 42 (51.2%) cases, negative in 26.8% (n=22) cases and 22% were u�k��w�. T�� HER2 �������� ����u� w�� ������v� �� 22 ����� (26.8%) were HER2 receptors evaluated as positive and negative in 60 cases (73.2%). Fig. 1 ���w� ��� IHC ���ul�� ��� ��������-11. I� m�l�g���� tissue samples, 25 cases (30.5%) exhibited strong positivity for cadherin-11, 34 cases (41.5%) had moderate positivity, and weak positivity in another 21 cases (25.6%). Of 82 cases, only two (2.4%) were negative for cadherin-11. As for benign/���l��y samples, only 8 cases (11.4%) exhibited strong positivity for cadherin-11, 12 (17.1%) were moderate positive, and 13 (18.6%) were weak positive. However, more benign/���m�l ����u�� ������ ��g���v� ��� ��������-11 ���� m�l�g���� �um��� (52.9 vs. 2.4%, respectively). This difference was statistically significant (P<0.0001).
C����l������ b��w��� ��������-11 ������� ���������� ��� ����� �l�����l-�����l�g���l ����m����� ��� ���w� �� T�bl� II. T�� ���������� �� ��������-11 ������� w�� ��� �����l���� w��� ������� �g�, �um�� ��z�, g�����g, �� ���m��� ��������� ����u�. T�� ���������� �� ��������-11 mRNA �� m�l�g���� ����u�� (black lanes 1-12) vs. benign/healthy tissues (white lanes 13-24) �� ���w� �� Fig. 2 . T�� ���������� �� ��������-11 mRNA l�v�l� b��w��� m�l�g����, ��� b���g� ���/�� ���l��y ����u� ��m�l�� was statistically significant (P=0.040).
Discussion
The present study demonstrates a significant difference in both mRNA ������������� ��� ������� ���������� �� ��������-11 �� m�l�g���� b����� ����u�, w��� ��m����� �� b���g� ���/�� healthy tissue. These findings are consistent with past research ��� �u����� �m�����z� ��� ��l� �� ��������� �� ��� �u���m����l mechanics of the disease (3, 5, 6, 13, 19) . Furthermore, this also points to the suspected role of cadherin-11 in EMT (12) (13) (14) (15) (16) (17) 19) .
Ou� ���ul�� ��� �� �g���m��� w��� ��� ���� �� P���-v���� et al (6) , w�� ���m���� ��� ���������� �� ��������-11 �� b����� ������ ��ll l���� ��� ��m��������� ���� ��������-11 mRNA ��� ������� w��� ��������� �� ��� m��� ��v���v� ��ll l����, bu� ��� �� ��y �� ��� �����v���v� ��ll l����. B���� �� ����� ���ul��, �� �� ����������� ���� ��������-11 ���������� m�y b� w�ll �����l���� w��� ��� ��v���v� ������y�� �� ������ ��ll� ��� ��ul� ���v� �� � m�l��ul�� m��k�� ��� ��� m��� �gg�����v�, ��v���v� �ub��� �� b����� �um���. P���v���� et al (6) �������� that cadherin-11 expression was significantly upregulated in m�l�g���� ����u� ��m�l�� ��� ���� �� w�� l���l�z�� �� ��� ��ll m�mb���� �� ��� m�l�g���� ��ll�, w���� �� �l�� �� l��� w��� ��� ���ul�� ��������� �� Fig. 1 . S�m�l��ly, ��� ���������� �� mRNA ���������� �� m�l�g���� ��� b���g� ����u� ��m�l�� w�� statistically significant (P=0.040) in the present study (Fig. 2) . C�������-11 w�� �����������lly ��������� �� b���l-l�k� b����� cancer (13) . T�� ����������� b��w��� ���������� �� ��������-11 ������� ��� g�����g �� ���m��� ��������� ����u� w��� ��� statistically significant in our study. There was also no correla-���� b��w��� �����g�� ��� ���g�������� ��������� �� m�l�g���� breast tissue samples (Table II) . The lack of correlation may be due to the median age of the sample group (51 years), since �l���, ����-m�����u��l w�m�� ��� m��� l�k�ly �� ��v�l�� �����g�� �������� ������v� b����� ������. P��v��u� ��u���� ��v� ��m��������� ���� ����� �� �� ��l��������� b��w��� �g� ��� progesterone receptor positivity (25) (26) (27) .
The present study was limited in several ways. Firstly, the control group consisted of tissue samples with undefined benign pathologies, which may influence the expression profile �� ���������. S�����ly, ��� ������� ���������� �� ��������-11 w�� ������m�� u���g �mmu����������m����y, w���� �� �ubj����v�, ��� ������ �v�lu����� �� ��� ����� �� l��k��g. W� �l�� l��k�� �l�����l ���� �� b��� m���������, w���� ��ul� ��v� ���v�� ��l�v��� �� ���� ��u�y.
T�� �u����� ��u�y �u������� �� ��m���������g ���� ��������-11 ���������� �� u���gul���� �� ��v���v� �um�� b����� ������. W� �y�������z� ���� ��� ���������� ������� � m��� m������ym�l ��llul�� ������y��, w���� ���m���� ��v�-���� ��� m��������� �� ��v���v� �um���.
C�������-11 �� � m�j�� �������u��� ���g�� �� ���um����� arthritis (10, 21) . U���g � ��w ���������m�m����� ��m�u-tational drug repurposing method, it was identified that the drug celecoxib, a United States Food and Drug Administration approved drug, and 2,5-dimethyl-celecoxib, a celecoxib ���l�gu� w����u� �y�l���yg����� 2 ����b����y ����v��y, ��� ��� structural potential to bind cadherin-11 (22) . A� ��������-11 may be an important target in cancer progression (21, 28) , this finding could potentially translate into clinical applica-���� �� ������ ������y. I� ����lu����, �u� ���ul�� �������� ���� ��������-11 ���������� �� u���gul���� �� m�l�g���� �um�� b����� ������. B���� �� ��� ���� ���� ��������-11 �� �y����lly ��������� �� ��ll� �� m������ym�l ���g��, ���� �ugg���� ���� EMT ���k �l���. T���� ���� �ugg��� ���� ��������-11 �� �m���-���� ��� m�l�g���� ���g������� ��� �� � ��������l �������u��� ���g�� �� b����� ������.
